Lineage Cell Therapeutics Announces Data From Vision Restoration Program Published in Stem Cells and Development Journal

CARLSBAD, Calif.--(BUSINESS WIRE)--<a href="https://twitter.com/search?q=%24LCTX&src=ctag" target="_blank">$LCTX</a> <a href="https://twitter.com/hashtag/AMD?src=hash" target="_blank">#AMD</a>--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that its paper entitled “Transplantation of Human Embryonic Stem Cell Derived Retinal Tissue in the Subretinal Space of the Cat Eye,” (Singh et al.), has been selected for publishing and will be featured on the cover of the September 2019 issue of Stem Cells and Development Journal, Volu

Full Story →